Granulocyte colony-stimulating factor for intracytoplasmic sperm injection patients with repeated implantation failure: which route is best?†

Zeyneloglu, Hulusi Bulent; Tohma, Yusuf Aytaç; Önalan, Göğşen; Moran, Utkun

doi:10.1080/01443615.2019.1631772

Cited by 19 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, 112 patients were randomized to receive subcutaneous GCSF 1 hour prior to day 3 embryo transfer or no intervention, resulting in an adjusted odds ratio of 2.63 (1.09-6.96) for implantation rate. The findings are consistent with at least one other recent retrospective cohort study in an RIF population 73 . While repeated demonstration in subsequent RCTs would support more widespread use of this intervention, existing evidence suggests minimal harm and potential benefit to this therapy in indicated patients with unexplained RIF.…”

Section: Endometrial Injury or "Scratch"supporting

confidence: 92%

Diagnostic and therapeutic options in recurrent implantation failure

Moustafa

Young

2020

F1000Res

View full text Add to dashboard Cite

Recurrent implantation failure (RIF) is an uncommon, imprecisely defined clinical disorder characterized by failure to achieve pregnancy after repeated embryo transfers. The diverse etiologies and incomplete understanding of RIF provide significant diagnostic and therapeutic challenges to patients and providers. Careful clinical evaluation prior to assisted reproduction can uncover many treatable causes, including thyroid dysfunction, submucosal myomas, and tobacco use. The more-subtle causes often require a more-targeted assessment. Undetected, small polyps or small areas of intrauterine synechiae are relatively common and easily treated contributors to RIF. Molecular and cellular abnormalities pose a greater therapeutic challenge. Putative causes of RIF, including progesterone resistance, shifted window of receptivity, decreased integrin expression, and immunologic disturbances, should be considered in the evaluation of a patient with otherwise unexplained RIF. It may also be true that a more complex and standardized definition of RIF would be helpful in these cases. In this paper, we review the diagnostic and therapeutic approaches to RIF, with emphasis on disorders of endometrial receptivity.

show abstract

Section: Endometrial Injury or "Scratch"supporting

confidence: 92%

Diagnostic and therapeutic options in recurrent implantation failure

Moustafa

Young

2020

F1000Res

View full text Add to dashboard Cite

show abstract

“…The SC route is used more often in patients with a history of RM, while the IU route is applied more often in cases of RIF or thin endometrium (Table 1). 49 …”

Section: Discussionmentioning

confidence: 99%

“…CPR was significantly higher in the group that received IU + SC G‐CSF (group 1 = 52.6% [20/38], group 2 = 64.1% [25/39], and group 3 = 323.5% [8/34], P = .002) than in other groups. LBR was also significantly higher in the group that received combined G‐CSF (group 1 = 34.2% [13/38], group 2 = 64.1% [25/39], and group 3 = 23.5% [8/34], P = .001) than in other groups 49 …”

Section: Discussionmentioning

confidence: 99%

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

Cavalcante

Sarno

et al. 2020

American J Rep Immunol

View full text Add to dashboard Cite

Studies have investigated the gestational outcomes of new immunological therapies in the treatment of patients with recurrent implantation failure (RIF) in assisted reproductive technology (ART). The objective of this article is to assess the current state of evidence available in the literature on intrauterine perfusion immunotherapies in women undergoing ART treatments. By considering the guidelines of Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA), the authors performed systematic review by searching the databases of PubMed/MEDLINE and Scopus using the following key words: “recurrent implantation failure,” “intrauterine infusion,” “Platelet‐Rich Plasma (PRP),” “Peripheral Blood Mononuclear Cells (PBMC),” “Granulocyte Colony‐Stimulating Factor (G‐CSF),” and “Human Chorionic Gonadotropin (hCG).” The authors analyzed the indications and the impact of new immunological therapies with intrauterine infusions on the pregnancy outcomes of patients undergoing ART. PRP, PBMC, G‐CSF, and hCG were the four most used immunological therapies with intrauterine infusion. These new therapies appear to improve the results of ART treatments in cases of RIF. However, the small number of studies does not allow definitive conclusions about the effectiveness of these therapies.

show abstract

“…Another, a consistent conclusion has been reached by Ying Jiang et al [27], in which subcutaneous injection was better. Nevertheless, a retrospective study in women undergoing IVF/ICSI treatments by Hulusi Bulent Zeyneloglu [10] showed that dual administration of G-CSF was signi cantly more effective than the only method. Combined with our study, the positive effect of G-CSF on pregnancy outcomes in patients with RIF women should be a rmed, but the route of administration needs further study.…”

Section: Comparison With Previous Studiesmentioning

confidence: 99%

“…In recent years, it has been found that the biological function of G-CSF is not limited to the blood system [8]. G-CSF seems play an important role in reproductive medicine, which is being administered mainly in women with thin unresponsive endometrium undergoing IVF [9], repeated IVF failures [10], unexplained recurrent pregnancy losses [11], improve the process of embryo implantation [12]and endometrial receptivity [13]. Many studies have con rmed that the pregnancy outcomes have been improved in patients undergoing IVF-ET [14,15].…”

Section: Introductionmentioning

confidence: 99%

Effect of Intrauterine Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF) Infusion on Pregnancy Outcomes in Patients With Repeated Implantation Failure During Freeze-Thaw Embryo Transfer Cycles: A Retrospective Cohort Study

Lyu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Repeated implantation failure (RIF) is one of the difficulties that hinder the further improvement of clinical pregnancy rate by assisted reproductive technology. RIF has become an urgent clinical problem and hot research topic in the field of assisted reproduction, which is also a challenge for clinicians.Objective: The aim of this study was to evaluate the effects of intrauterine recombinant human granulocyte colony-stimulating factor(rhG-CSF) to improve implantation, clinical pregnancy, early abortion, multiple pregnancy and live birth rate(LBR) rate in women with RIF. Methods: A retrospective clinical analysis involving 142 women with RIF was conducted in the reproductive Medicine Center, the First Hospital of Lanzhou University between 1 January 2015 and 30 June 2018. They were divided into two groups: rhG-CSF group and control group, according to whether or not intrauterine rhG-CSF. In rhG-CSF group (n=47) granulocyte colony-stimulating factor (300 micrograms in 1 mL) was infused into the uterus within five minutes by embryo transfer cathete during the proliferative period of menstrual cycle before freeze-thaw embryo transfer(FET), while the control group was not given intrauterine perfusion. The implantation, clinical pregnancy, early abortion and multiple pregnancy were compared between the two groups. Results:The mean age for whole study group was 35.3±4.2 years old. There were no significant differences between demographic characteristics in two groups(p>0.05). The successful implantation (28.44% vs 12.44%, p=0.012), and clinical pregnancy (48.95% vs 27.35%, p=0.011) rates were significantly higher in the rhG-CSF group than in the control group. Binary logistic regression indicated that rhG-CSF treatment remained significantly associated with successful clinical pregnancy(OR=2.979, 95% CI=1.262-7.003).Conclusion: Intrauterine infusion of rhG-CSF can increase embryo implantation rate, clinical pregnancy rate in patients with RIF. In addition, the age and rhG-CSF are the independent risk factors affecting pregnancy outcomes.

show abstract

Granulocyte colony-stimulating factor for intracytoplasmic sperm injection patients with repeated implantation failure: which route is best?†

Cited by 19 publications

References 29 publications

Diagnostic and therapeutic options in recurrent implantation failure

Diagnostic and therapeutic options in recurrent implantation failure

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

Effect of Intrauterine Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF) Infusion on Pregnancy Outcomes in Patients With Repeated Implantation Failure During Freeze-Thaw Embryo Transfer Cycles: A Retrospective Cohort Study

Contact Info

Product

Resources

About

Granulocyte colony-stimulating factor for intracytoplasmic sperm injection patients with repeated implantation failure: which route is best?†

Cited by 19 publications

References 29 publications

Diagnostic and therapeutic options in recurrent implantation failure

Diagnostic and therapeutic options in recurrent implantation failure

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

Effect of&nbsp;Intrauterine Recombinant Human Granulocyte Colony-stimulating Factor&nbsp;(rhG-CSF) Infusion on Pregnancy Outcomes in Patients With Repeated Implantation Failure During Freeze-Thaw Embryo Transfer Cycles: A Retrospective Cohort Study

Contact Info

Product

Resources

About

Effect of Intrauterine Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF) Infusion on Pregnancy Outcomes in Patients With Repeated Implantation Failure During Freeze-Thaw Embryo Transfer Cycles: A Retrospective Cohort Study